Clinical trials: Severe COVID-19
SARS-CoV Infection, Polymerase Chain Reaction
Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR
This is a study that will attempt to validate the process for detecting SARS-CoV-2 (COVID19) on a non-FDA-approved technology using self-collected saliva as the specimen.
- Conditions
- SARS-CoV Infection, Polymerase Chain Reaction, Laboratory Testing
- Trial name
- NCT04604145
- Testing
- SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- David Grant U.S. Air Force Medical Center
COVID-19
Ivermectin for Severe COVID-19 Management
In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause…
- Trial name
- NCT04646109
- Testing
- Ivermectin
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Afyonkarahisar Health Sciences University
COVID-19
Infliximab in the Treatment of Patients With Severe COVID-19 Disease
In this trial, patients that are severely affected by the disease COVID-19 will either receive infliximab, an anti-inflammatory drug, or standard therapy.
- Trial name
- INFLIXCOVID (NCT04922827)
- Testing
- Infliximab, Standard of Care
- Where
- 4 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Jena University Hospital
Microbiome,Immune Function, Critically Ill
Microecology and Host Immunity in Patients With Severe COVID-19 Infection
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the prognosis of patients with severe COVID-19.
- Trial name
- NCT05670275
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Covid19
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
This is an interventional, multicenter, 2-arm, parallel-group, randomized, double-blind, placebo controlled, dose-escalation, safety and efficacy study of F-652 treatment versus placebo in patients aged 18 years or older with a…
- Trial name
- NCT04498377
- Testing
- F-652
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EVIVE Biotechnology
SARS-CoV-2 Acute Respiratory Disease, Covid19
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
During this pandemic period, the goal of the health care system is to optimize the use of intensive care services for patients infected with SARS-CoV-2, given the frequency of complications that can lead to high mortality.
- Trial name
- STC-19 (NCT04371471)
- Testing
- STC-19 score
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Coronavirus Disease 2019 (COVID-19) Pneumonia
Saliva PCR in Pregnant Women with COVID-19
Abstract: Objectives We aim to study the relative viral load using saliva polymerase chain reaction among pregnant women treated with Paxlovid.
- Trial name
- NCT06735300
- Testing
- Nirmatrelvir/Ritonavir (Paxlovid)
- Where
- Taiwan
- Volunteers
- 37 people
- Sponsor
- National Cheng-Kung University Hospital
Covid19, Severe COVID-19 Patients
Role of Co-trimoxazole in Severe COVID-19 Patients
Coronavirus Disease 19 (COVID-19) is a global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Severe disease occurs in 15% of the cases with COVID-19 and may progress to critical disease in only…
- Trial name
- NCT04470531
- Testing
- oral co-trimoxazole
- Where
- Bangladesh
- Volunteers
- 94 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Covid19, Covid-19 ARDS
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04678739
- Testing
- Remdesivir, Tocilizumab
- Where
- 4 sites in Bangladesh
- Volunteers
- 205 people
- Sponsor
- M Abdur Rahim Medical College and Hospital
Covid19
Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at…
- Trial name
- NCT04646031
- Testing
- T89 capsule
- Where
- United States
- Sponsor
- Tasly Pharmaceuticals, Inc.
Covid19
TOcilizumab and Covid-19 : Risk of Severe INfection
SARS-CoV2 is responsible for a pandemic that has been evolving for approximately 18 months. The virus' capacity for dissemination and its virulence are responsible for significant morbidity and mortality.
- Trial name
- TOCSIN (NCT05017441)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Sepsis
Assessement of Microcirculation With NIRS Predicts Sepsis Development in Patients With Severe Covid-19 Pneumonia
Sepsis and septic shock are among main causes of death in patients with severe Covid-19 pneumonia. A few factors are proven to predict sepsis in these patients.
- Trial name
- NCT06360770
- Where
- Slovenia
- Volunteers
- 35 people
- Sponsor
- General and Teaching Hospital Celje
Covid19, Follow up
Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19)
Patients affected by new coronavirus infectious disease (COVID) were mostly hospitalized in ICU. This infection seems to cause widespread organ injury (i.e acute renal injury, neurological disorders, pulmonary embolism,…).
- Conditions
- Covid19, Follow up, Rehabilitation
- Trial name
- NCT04491214
- Testing
- quality of live assessment
- Where
- France
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Severe Acute Respiratory Syndrome Coronavirus 2
Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections
The study objective is to investigate the diagnostic value and consistency of chest CT as compared with comparison to RT-PCR assay in COVID-19 in patients which were stratified for hospital admission.
- Trial name
- SCout (NCT04357938)
- Testing
- CT-imaging
- Where
- Germany
- Volunteers
- 145 people
- Sponsor
- Jena University Hospital
SARS-CoV-2
Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina
Background The study aimed to establish the seroprevalence of SARS-COV-2 in an Argentinian slum three months after the first case was reported.
- Trial name
- NCT04472078
- Testing
- Serological Assay or IgG for SARS-CoV-2
- Where
- Argentina
- Volunteers
- 873 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19 Respiratory Infection, Rehabilitation
Efficacy of Respiratory Rehabilitation After COVID-19 Severe Infection
The purpose of this study is to investigate the effects of a training program in patients that have suffered a COVID infection
- Conditions
- COVID-19 Respiratory Infection, Rehabilitation, Physical Therapists
- Trial name
- COVFIS2021 (NCT05307562)
- Testing
- Interval training + analytical strength, Interval training + analytical strength and IMT
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Respiratory Syndrome, Acute, Severe, Hypoxic Respiratory Failure
Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure
Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF.
- Conditions
- Respiratory Syndrome, Acute, Severe, Hypoxic Respiratory Failure, Viral Pneumonia
- Trial name
- NCT04385823
- Testing
- patients receiving nasal high flow
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Hôpital Louis Mourier
Covid19
Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
This is multicenter clinical trial to evaluate efficacy and safety of Baricitinib in treatment for COVID-19. This trial will compare Baricitinib, a drug recommended for Rheumatoid Arthritis, against standard of care, to assess…
- Trial name
- NCT05056558
- Testing
- Baricitinib
- Where
- Bangladesh
- Volunteers
- 480 people
- Sponsor
- Incepta Pharmaceuticals Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.